Nucleoside derivatives for treating hepatitis C virus infection

Details Nucleoside derivatives for treating hepatitis C virus infection Nucleoside derivatives for treating hepatitis C virus infection

2003-09-30

2008-09-16

Crane, L. E. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S047000, C536S026230, C536S026260, C536S026700, C536S027630

Reexamination Certificate

active

07425547

ABSTRACT:
Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula IB as follows:and pharmaceutically acceptable prodrugs and salts thereof, where R, R1, R13, R14, W, W2, W3, Y and Z are as defined herein.

REFERENCES:
patent: 5430027 (1995-07-01), Knutsen et al.
patent: 5681941 (1997-10-01), Cook et al.
patent: 5763167 (1998-06-01), Conrad
patent: 5977332 (1999-11-01), Martin
patent: 6211154 (2001-04-01), Scarborough et al.
patent: 6475985 (2002-11-01), Wagner et al.
patent: 6500946 (2002-12-01), Takamatsu et al.
patent: 6586413 (2003-07-01), Liang et al.
patent: 6660721 (2003-12-01), Devos et al.
patent: 6703394 (2004-03-01), Engelhardt et al.
patent: 6777395 (2004-08-01), Bhat et al.
patent: 7094768 (2006-08-01), Roberts et al.
patent: 2003/0130226 (2003-07-01), Loakes et al.
patent: 2007/0015905 (2007-01-01), LaColla et al.
patent: 2007/0032449 (2007-02-01), LaColla et al.
patent: 1117669 (2000-04-01), None
patent: WO/94/18215 (1994-08-01), None
patent: WO/95/07919 (1995-03-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO/03/061576 (2003-07-01), None
patent: WO03/061576 (2003-07-01), None
patent: WO/2004/028481 (2004-04-01), None
patent: WO/2004/065398 (2004-08-01), None
Bowler et al., “New Adenosine A3 Ligands Controlling Cytokines,” Drug Development Research, 37, 173 (bottom of col. 2) (Mar. 1996).
Jacobson et al., “Recent Developments in Selective Agonists and Antagonists Acting at Purine and Pyrimidine Receptors,” Drug Development Research, 39(3-4), 289-300 (1996).
Beigelman et al. “New Syntheses of 2′-C-Methylnucleosides Starting from D-Glucose and D-Ribose”Carbo. Research,166:219-232 (1987).

Affiliated with

Also associated with

Rating

Nucleoside derivatives for treating hepatitis C virus infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleoside derivatives for treating hepatitis C virus infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside derivatives for treating hepatitis C virus infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3991844